trending Market Intelligence /marketintelligence/en/news-insights/trending/Py0bLWbpsuQjl_I2-v5Yug2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Matinas raising $30M from common stock offering to fund pipeline development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Matinas raising $30M from common stock offering to fund pipeline development

Matinas BioPharma Holdings Inc. priced an offering of 27,272,727 shares at $1.10 apiece to raise $30.0 million in gross proceeds.

BTIG LLC, the sole book-running manager for the offering, has an option to buy up to an additional 4,090,909 of the biopharmaceutical company's shares.

Bedminster, N.J.-based Matinas BioPharma said it plans to close the offering on or around March 19.

Net proceeds from the offering will be used to fund ongoing development activities of Matinas' potential drugs, including MAT9001 in the treatment of heart and metabolic conditions, and its lipid nano-crystal platform delivery technology, which can make medicines safer, more tolerable, less toxic and orally bioavailable.

In addition, the proceeds will be used to fund working capital and other general corporate purposes.